US and French regulators have given Oxford BioMedica the go ahead to restart studies of three eye drugs it is developing with Sanofi after an impurity found in trial materials was identified as a harmless culture media derivative.
Despite the popularity of transgenics and the potential it is seen
to hold for the future of biopharmaceutical production, Viragen has
decided to drop development of its OVA system - therapeutic protein
production in transgenic hen...
Oxford Biomedica has made available preclinical efficacy data,
which suggests that gene-based product could have significant
efficacy for those suffering from Parkinson's disease when compared
to current treatment methods.
British gene therapy firm Oxford Biomedica has licensed its VSV-G
viral envelope technology for gene delivery to American biotech
company VIRxSYS which hopes it can use it to successfully produce
its promising anti-HIV/AIDS product...
Scientists have successfully achieved the production of a
functional humanised antibody in the whites of eggs laid by a
transgenic hen, opening the door to using transgenic flocks as an
alternative to mammalian cell culture for the...
Oxford BiomMedica has entered into a partnership with a US company
to try to overcome the primary obstacles to producing recombinant
proteins in eggs, the low level of expression of the gene
transcript coding for the target protein...